APTOSE PRESENTS SAFETY, RESPONSE, AND MRD CLINICAL DATA FROM TUSCANY PHASE 1/2 CLINICAL TRIAL OF TUSPETINIB TRIPLET THERAPY IN NEWLY DIAGNOSED AML AT THE 2025 EHA CONGRESS

Reuters · 06/12 16:00

Please log in to view news